MorphoSys AG Reports Fourth Quarter and Full Year 2021 Finan

Monjuvi U.S. net product sales of US$ 23.6 million (€ 20.5 million) for the fourth quarter and US$ 79.1 million (€ 66.9 million) for the full year 2021 Pipeline advances: enrollment progressing across

Related Keywords

Germany , Boston , Massachusetts , United States , Canada , United Kingdom , Planegg , Bayern , American , German , Thomas Biegi , Julia Neugebauer , Jean Paul Kress , Myles Clouston , Jeanette Bressi , American Society Of Hematology Annual Meeting , Xencor Inc , Linkedin , Twitter , Nasdaq , Morphosys Group Key Figures , Meeting Of The American Society Nephrology , Constellation Pharmaceuticals , National Comprehensive Cancer Network , Mother Program , Development Funding Bonds , Drug Administration , European Commission , Us Communications , Exchange Commission , Development Rd Expenses , Health Canada , Chief Executive Officer , Paul Kress , American Society , Hematology Annual Meeting , Clinical Practice Guidelines , Program Highlights , Royalty Pharma , Royalty Pharma Investments , Fourth Quarter , Net Profit Loss , Full Year , Product Sales , Sys Group Key Figures , Operating Expenses , Tax Benefit , Net Profit , Financial Statements , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Morphosy Annual Report , Morphosys , Reports , Fourth , Quarter , Bull , Ear , 021 , Financial , Results , Rovides , Corporate , Update ,